Neometals {ASX: NMT} have announced a very substantial increase in the resources at Mt. Marion after an updated report conducted by Snowden Consultants.

Contained lithium has increased some 160%.

News release by Neometals 6th July 2016

Neometals announce a substantial increase in resources at Mt. Marion.

Neometals {ASX: NMT}  – We are pleased to provide a new Mineral Resource Estimate for the Mt Marion Lithium Project, prepared by Snowden Mining Industry Consultants.

The results of the study have increased the Mineral Resource Estimate to Indicated and Inferred Mineral Resources of 60.5 Mt at 1.36% Li2O and 1.09% Fe, at a cut-off grade of 0.3% Li2O, compared to 23.24 Mt at 1.39% Li2O, at a cut-off grade of 0% Li2O previously.

This represents a substantial increase in the size of the mineral resource, equating to a 160% increase in the total contained lithium at the Project.

To read the full news release on PDF please click HERE

TSX listed junior mining companies are finally completing financings and bought deals once again, after what seems like an eternity.

These are more than keep the lights on and pay the rent financings, for significant sums of money that allow projects to advance and add value.

As the mining sector fell into the depths, one aspect that kept the negative momentum going was the unavailability of finance, creating “zombie” companies with negative working capital.

Now, finally, some financings are occurring again, and of course they are being done by the better quality companies, run by competent management teams, some in production already, and others with a good project in a safe jurisdiction.

Recent examples are Mandalay Resources (raised $35 million), Nu Legacy Gold, ($3 million), Excellon Resources ($10 million), and TerraX, ($7 million).

All these are significant sums of money, raised by companies that I recognise as being well run and have a good management team and project.

Mandalay are in production,as are Excellon, NuLegacy gold and TerraX have strong exploration projects in Nevada and Quebec respectively, both top jurisdictions for gold exploration and responsible government.

it’s a relief to see such sums being raised, even if the financiers are being selective about whom they invest in, and they are quite right to do that of course.

I wonder how long it will be before we see the return of the Vancouver Stock promoter? He’s been lying low for a while now, with money being made again, it can’t be long before he emerges from under his rock to try and gain some of the new wealth.

The lesson is invest in quality companies, there are still zombies about, and any raise they do will be used to reduce negative working capital, paying outstanding salaries and bills, with little or nothing going into the ground where it could possibly increase shareholder value.

Caveat emptor!

Nymox Pharmaceutical (Nasdaq: NYMX) stock has climbed nearly 45% in the last 8 trading days.

The reason is the recent announcement of their prostrate cancer study results.

Nymox Pharmaceutical (Nasdaq: NYMX) stock climbed nearly 45% in under two weeks after their recent new release.

The company recently reported long-term prostate cancer results in 7 year prospective study of 995 middle-aged and elderly men without cancer in the US.

The trial showed the men who received fexapotide had a major reduction in incidence of prostate cancer.

To read the full press release, click HERE

The price of Silver has risen just under 50% since the start of 2016.

Often consider an unfashionable precious metal, due to its industrial uses, “gold’s poor cousin” is storming ahead.

As a result of the recent rise in the price of silver, the gold silver ratio has fallen slightly, from over 70:1  to 66:1 now.

Current political and economic volatility is contributing to the vertiginous rise.

What’s not so clear is why silver is increasing slightly faster than gold?

To check the live silver price, click HERE

Nymox Pharmaceutical Corp. {NASDAQ: NYMX} Director James George Robinson acquired 17,500 shares of the business’s stock in a transaction dated Wednesday, June 29th.

This purchase continues his buying spree,and he now holds over 2.8 million shares.

Comment

If you need an example of a director showing a massive vote of confidence in his own company by buying in the market, this has to be it.

George Robinson’s continuing purchases now mean he has accrued over $10 million worth of shares at the current price of around $3.53 per share.

So refreshing to see a director putting his own money in at market prices, and with the recent news, I hope he coins it in in the future because he deserves it in my opinion.

Nymox Pharmaceutical Corp. {NASDAQ: NYMX} Director James George Robinson acquired 17,500 shares of the business’s stock in a transaction dated Wednesday, June 29th.

The stock was purchased at an average price of $3.53 per share, for a total transaction value of $61,775.00.

Following the completion of the acquisition, the director now owns 2,833,050 shares in the company, valued at $10,000,666.50 at the current market price.

Condor Gold {AIM: CNR} has issued an Exploration update on the La India Project, located in Nicaragua, Central America.

Condor have also announced a new addition to their geological team..

TIDMCNR

RNS Number : 8785C

Condor Gold PLC

01 July 2016

Exploration update on the La India Project

For the PDF with maps, please click HERE

Condor {AIM: CNR}, is pleased to provide an update on regional exploration activity at the La India Project, Nicaragua. Amongst the activities undertaken by Condor during the first half of 2016 are:

Highlights

— Follow up field work on 33 exploration targets identified in a structural geology study and 13 exploration targets identified by the on-going soil survey as at the end of 2015

— Initial success highlights a 12.5 km mineralised corridor 9 km north of the main La India open pit resource with high grade rock chip of 53.9 g/t gold

— Soil survey expanded to cover the remaining 242 km(2) of La India Project to delineate further prospects and demonstrate the district scale gold potential

— Dr Warren Pratt has joined Condor as a senior geological consultant and will focus on the exploration upside. He is producing a detailed geological, stratigraphic and structural map of La India Project.

Mark Child CEO comments:

“Following on from the successful structural geology study last year, which identified 33 new exploration targets, and a 71 km(2) soil survey that identified an additional 13 new exploration targets, Condor recently initiated a further 242 km(2) soil survey programme at La India Project aimed at identifying additional prospects and demonstrating the district-scale gold potential of La India Project. Recent work by Condor geologists has identified a 12.5 km long mineralised corridor 9 km to the north of La India open pit. A high grade rock chip of 53.9 g/t gold at the northern end of the Andrea-Limones mineralised corridor, some 6 km away from the nearest gold mineral resource, is highly encouraging. Follow up trenching is being planned in the area.

I am delighted that Dr Warren Pratt has joined Condor as a senior geological consultant. He will advise the Board on the exploration upside of La India Project. Earlier this month he spent two weeks at Mina La India and will lead the production of a detailed geological, stratigraphic and structural map across the entire District. Dr Pratt contributed to the due diligence ahead of the recent investment in the Company by Ross Beaty and strengthens the geological team.”

Background

In 2015 Condor geologists completed a regional B-horizon 53 element ultra-trace soil geochemistry survey (a soil survey) comprising 6,156 samples covering 71 km(2). This included an initial phase of 5,767 samples over 55 km(2) on a 200m by 50m grid with some 100 m x 50 m infill sampling in La India South – Mojarra Area and a second phase of 389 samples over 16.3 km(2) collected on a 400 m by 100 m grid over the interpreted northwest strike extension of the El Tanque structure. A detailed review of the results identified thirteen exploration targets, including five priority targets with overlapping gold, upflow and high level indicators and a further seven targets with coincident gold and upflow indicators.

Also in 2015 senior consultant structural geologist Dr Tony Starling of Telluris Consulting Ltd completed a study on the structural geology of the La India Gold District. This work represented a stepwise improvement in our understanding of the structural evolution of the district geology and defined the favourable structural orientations that control the flow and deposition of epithermal gold. Dr Starling identified 33 exploration targets, 23 of which have known gold veining at surface (See RNS dated 15(th) September 2015).

Follow up of exploration of targets

Follow up geological mapping and prospecting has been carried out over the majority of the areas covered by the soil survey and structural geology study since the fourth quarter of 2015.

During this period a total of 114 rock chips were sampled (figure 1) of which 15 samples have come back with gold values of 1-5 g/t and 6 samples with gold values > 5 g/t, including a 53.9 g/t sample from a new site in the Los Limones area, at the very northwest end of the Andrea vein structure. This is significant when put into the context of the high level epithermal characteristics observed in this area, including opaline quartz, sinter and silicified wood fragments.

Some highlights of the follow up work are:

— Several rock chips with anomalous gold values identify a possible NW striking 1.5 km structure to the southeast of the El Tanque prospect. This structure was identified as a target in Dr Starling’s structural geology analysis. Rock chips have characteristic high level quartz textures and lie 70-140 m topographically above high grade samples in the main El Tanque prospect (figure 1), possibly indicating that mineralization at depth can be extended to the southeast.

— The soil survey identified a gold anomaly along a corridor that extends from the southernmost surface exposure of the Andrea vein down to the Cristalito prospect, approximately 4.5 km to the southeast. Prospecting to date has not been able to identify a surface expression of the continuity of the Andrea vein to the southeast, but high level textures and surface silica deposits identified recently, may represent the surface expression of a deeper level mineralized structure that connects the Andrea vein with the Cristalito prospect.

— To the northwest of the Andrea vein, several rockchips with anomalous gold values and boiling textures were collected in an area previously not sampled that connects the Andrea vein to the Los Limones area, where high grade veins have been sampled, including a 53.9 g/t Au. These findings indicate that the NW mineralised corridor possibly extends for 12.5 km from the Cristalito prospect northwest to Los Limones area.

.

District wide soil sampling

During the first week of June 2016, Condor initiated a district wide soil sampling survey to cover the remaining areas of Condor Gold’s concession package in La India project, not covered by the 2015 survey. An estimated total of 6,300 samples will be collected covering an approximate area of 242 km2.

The fine-fraction B-horizon soil samples will be analysed for 53 elements at ultra-trace detection limits at Bureau Veritas Laboratories in Vancouver using standard ICP-MS method.

The survey will be carried out using three different sampling spacings (figure 2). A core area covering the main area of known veins in La India concession will be sampled using a grid of 200 x 50 m. The northwest mineralized corridor within the El Rodeo concession will be sampled with a grid of 400 x 100 m. The rest of the areas within the concession package will be sampled at a wider spacing of 400 x 400 m.

Sampling and interpretation of results is planned to conclude by the end of 2016. Infill sampling of geochemical anomalies in the widely sampled areas will be conducted in 2017 to better define the prospects.

Geological mapping

Condor has engaged Dr. Warren Pratt of Specialised Geological Mapping Ltd. as a senior geological consultant who, together with Condor geologists, will carry out detailed geological, stratigraphic and structural mapping of La India District. Dr. Pratt will also train Condor’s geologists and establish a methodology for mapping and core logging in order to standardise data collection and interpretation procedures.

Dr. Pratt (BSc Geology, Hull, 1986; PhD Structural Geology, University of Wales, 1990) is the founder of Specialised Geological Mapping Ltd. and has a decade of British Geological Survey field experience and extensive world-wide field mapping experience in a great variety of geological terrains. Since 1995 he has worked extensively in gold, silver and copper exploration, including consulting on some World Class mineral deposits. These include Navidad (Argentina) and Ventana Gold (Colombia). Dr Pratt has a track record of generating gold/copper targets in under-explored areas, including the Cañicapa high sulfidation gold project, discovered during a World Bank program in Ecuador. He is also part of the team that recently discovered the Igor gold/silver epithermal deposit (Peruvian Precious Metals Corp) in Peru.]

Competent Person’s Declaration

The information in this announcement that relates to the mineral potential, geology, Exploration Results and database has been reviewed by Peter Flindell, Senior Geological Consultant, who is a Member of the Australian Institute of Geoscientists and Australian Institute of Mining and Metallurgy, and a geologist with thirty years of experience in the exploration and definition of precious and base metal mineral resources. Peter Flindell is a Non-Executive Director of Condor Gold plc and has sufficient experience which is relevant to the style of mineralization and type of deposit under consideration, and to the type of activity which he is undertaking to qualify as a Qualifying Person as defined in the June 2009 Edition of the AIM Note for Mining and Oil & Gas Companies. Peter Flindell consents to the inclusion in the announcement of the matters based on the information in the form and context in which it appears and confirms that this information is accurate and not false or misleading.

Technical Glossary
B-horizon The organic-poor soil horizon consisting
soil of typically brown coloured completely
weathered rock material with no primary
textures. This horizon often occurs
beneath the organic-rich A-horizon and
contains some organic material such
as roots are usually present.
———————— —————————————————
Assay The laboratory test conducted to determine
the proportion of a mineral within a
rock or other material. Usually reported
as parts per million which is equivalent
to grams of the mineral (i.e. gold)
per tonne of rock
———————— —————————————————
Geochemistry The study of the elements and their
interaction as minerals to makeup rocks
and soils
———————— —————————————————
Geophysics The measurement and interpretation of
the earth’s physical parameters using
non-invasive methods such as measuring
the gravity, magnetic susceptibility,
electrical conductivity, seismic response
and natural radioactive emissions.
———————— —————————————————
Hydrothermal Hot water circulation often caused by
heating of groundwater by near surface
magmas and often occurring in association
with volcanic activity. Hydrothermal
waters can contain significant concentrations
of dissolved minerals.
———————— —————————————————
ICP-MS (Inductively A technique that measures the concentrations
Coupled Plasma of elements in a substance, such as
Mass Spectrometry) a rock, by dissolving the substance
in a solution, typically an acid, ionizing
a sample and separating the ions to
measure the relative concentrations
based on their mass-to-charge ratio.
The technique is capable of measuring
very low concentrations with high precision.
———————— —————————————————
Magnetic (aeromagnetic) The measurement of the magnetic properties
survey of the earth surface as controlled by
the concentration and distribution of
magnetic minerals, particularly magnetite,
in the rock. Rocks containing higher
levels of iron, such as mafic igneous
rocks or some sedimentary rocks will
have a higher magnetic susceptibility
than felsic igneous rocks, siliciclastic
and carbonate sediments and their metamorphic
derivatives..
———————— —————————————————
Mineral Resource A concentration or occurrence of material
of economic interest in or on the Earth’s
crust in such a form, quality, and quantity
that there are reasonable and realistic
prospects for eventual economic extraction.
The location, quantity, grade, continuity
and other geological characteristics
of a Mineral Resource are known, estimated
from specific geological knowledge,
or interpreted from a well constrained
and portrayed geological model
———————— —————————————————
Mineral Reserve The economically mineable part of a
Measured and/or Indicated Mineral Resource.
It includes diluting materials and allowances
for losses, which may occur when the
material is mined. Appropriate assessments
and studies have been carried out, and
include consideration of and modification
by realistically assumed mining, metallurgical,
economic, marketing, legal, environmental,
social and governmental factors. These
assessments demonstrate at the time
of reporting that extraction could reasonably
be justified. Ore Reserves are sub-divided
in order of increasing confidence into
Probable Ore Reserves and Proved Ore
Reserves.
———————— —————————————————
Radiometric Also known as gamma ray spectrometry,
is the measure of natural radiation
on the top 30-45cm of the earth’s surface.
The abundance of the three naturally
occurring radioactive elements, potassium
(K), thorium (Th) and uranium (U), is
proportional to the abundance of minerals
containing those elements. This information
can be used in mapping the surface geology
including the definition of areas of
potassium enrichment related to hydrothermal
alteration.
———————— —————————————————
Rock chip A sample of rock collected for analysis,
from one or several close spaced sample
points at a location. Unless otherwise
stated, this type of sample is not representative
of the variation in grade across the
width of an ore or mineralised body
and the assay results cannot be used
in a Mineral Resource Estimation
———————— —————————————————
Stockwork Multiple connected veins with more than
one orientation, typically consisting
of millimetre to centimetre thick fracture-fill
veins and veinlets.
———————— —————————————————
Strike length The longest horizontal dimension of
an ore body or zone of mineralisation.
———————— —————————————————
Vein A sheet-like body of crystallised minerals
within a rock, generally forming in
a discontinuity or crack between two
rock masses. Economic concentrations
of gold are often contained within vein
minerals.
———————— —————————————————

– Ends –

For further information –  www.condorgold.com

Contact:
Condor Gold plc ,
Mark Child  Chairman and CEO non executive
020 74932734

 
About Condor Gold plc:

Condor Gold plc was admitted to AIM on 31st May 2006.

The Company is a gold exploration and development company with a focus on Central America.

Condor completed a Pre-Feasibility Study (PFS) and two Preliminary Economic Assessments (PEA) on La India Project in Nicaragua in December 2014. The PFS details an open pit gold mineral reserve of 6.9M tonnes at 3.0g/t gold for 675,000 oz gold producing 80,000 oz gold p.a. for 7 years. The PEA for the open pit only scenario details 100,000 oz gold production p.a. for 8 years whereas the PEA for a combination of open pit and underground details 140,000 oz gold production p.a. for 8 years. La India Project contains a total attributable mineral resource of 18.4Mt at 3.9g/t for 2.33M oz gold and 2.68M oz silver at 6.2g/t to the CIM Code.

In El Salvador, Condor has an attributable 1,004,000 oz gold equivalent at 2.6g/t JORC compliant resource. The resource calculations are compiled by independent geologists SRK Consulting (UK) Limited for Nicaragua and Ravensgate and Geosure for El Salvador.

Disclaimer

Neither the contents of the Company’s website nor the contents of any website accessible from hyperlinks on the Company’s website (or any other website) is incorporated into, or forms part of, this announcement.

This information is provided by RNS

The company news service from the London Stock Exchange

END

Range Energy Resources  {CSE: RGO} announced that it has received a loan totalling CDN $907,305 from an arm’s length party to continue to fulfill its obligations to joint venture participants in the Khalakan Block, located in the Kurdistan Region of Iraq.

Vancouver, BC, Canada – Range Energy Resources Inc.  {CSE: RGO} announces that it has received a loan totalling CDN$907,305  from an arm’s length party to continue to fulfill its obligations to joint venture participants so that the development of the Khalakan Block in the Kurdistan Region of Iraq can continue as well as provide general working capital.

The Loan is unsecured and evidenced by a loan agreement (the “Loan Agreement”) bearing an interest of 7% for the duration of the outstanding Loan, calculated and payable on demand.  The Company may pay the Loan in whole or in part, at any time without penalty.

As the CDN $907,305 is a loan from an insider bearing an interest of 7%, the Loan constitutes a “related party transaction” within the meaning of Multilateral Instruments 61-101 Protection of Minority Security Holders in Special Transactions (“MI 61-101”).  The Company relied upon the applicable exemptions under MI 61-101 from the formal valuation and minority shareholder approval requirements in relation to the Loan.

The Company also wishes to announce that the number of issued and outstanding common shares as at May 18, 2016 in the information circular was 819,405,977.

For further information on Range Energy Resources, please visit the Company’s web site, Click HERE

On Behalf of the Board of Directors:
Toufic Chahine
Chairman
+1 604 688 9600

Email: range@rangeenergyresources.com

THIS PRESS RELEASE, REQUIRED BY APPLICABLE CANADIAN LAWS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN. THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES OR TO U.S. PERSONS UNLESS REGISTERED OR EXEMPT THEREFROM.

This news release contains certain statements that may be deemed to include “forward-looking information”. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Range Energy believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of Range Energy’s management on the date the statements are made. Except as required by law, Range Energy Resources Inc. undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Barkerville Gold Mines {TSX.V: BGM} Intersects 30.98 G/T  Au Over 6.80 Metres In Cow Mountain Phase I Drilling.

A new Gold Extension has been Discovered.
June 29th, 2016

 
VANCOUVER, BC– June 29, 2016 – Barkerville Gold Mines. {TSXV: BGM}  is pleased to announce results from the Phase I drilling program on Cow Mountain at the Company’s Cariboo Gold Project (CGP).

Drilling Highlights:
BGM-16-280: 12.51 g/t (0.36 oz/t) Au over 9.70 metres including 17.95 g/t (0.52 oz/t) Au over 1.50 metres and 98.50 g/t (2.87 oz/t) Au over 0.87 metres
BGM-16-298: 30.98 g/t (0.90 oz/t) Au over 6.80 metres including 52.94 g/t (1.54 oz/t) Au over 3.60 metres including 144.50 g/t (4.21 oz/t) Au over 1.10 metres and 15.85 g/t (0.46 oz/t) Au over 1.00 metres
BGM-16-307: 34.79 g/t (1.01 oz/t) Au over 5.00 metres including 113.00 g/t (3.30 oz/t) Au over 1.10 metres and 42.60 g/t (1.24 oz/t) Au over 1.10 metres
BGM-16-315: 28.40 g/t (0.83 oz/t) Au over 3.00 metres including 70.10 g/t (2.04 oz/t) Au over 1.20 metres
BGM-16-326: 31.67 g/t (0.92 oz/t) Au over 2.90 metres including 11.40 g/t (0.33 oz/t) Au over 0.50 metres including 112.50 g/t (3.28 oz/t) Au over 0.70 metres
BGM-16-333: 10.62 g/t (0.31 oz/t) Au over 9.30 metres including 23.78 g/t (0.69 oz/t) Au over 2.90 metres including 42.40 g/t (1.24 oz/t) Au over 1.00 metres and 29.70 g/t (0.87 oz/t) Au over 0.70 metres
BGM-16-347: 119.69 g/t (3.49 oz/t) Au over 2.55 metres including 216.93 g/t (6.33 oz/t) Au over 1.40 metres including 317.00 g/t (9.25 oz/t) Au over 0.90 metres
BGM-16-349: 21.41 g/t (0.62 oz/t) Au over 5.90 metres including 50.90 g/t (1.48 oz/t) Au over 1.50 metres including 71.10 g/t (2.07 oz/t) Au over 0.70 metres
BGM-16-352: 28.45 g/t (0.83 oz/t) Au over 5.00 metres including 44.05 g/t (1.28 oz/t) Au over 3.00 metres including 43.50 g/t (1.27 oz/t) Au over 1.50 metres and 44.60 g/t (1.30 oz/t) Au over 1.50 metres
BGM-16-359: 22.84 g/t (0.67 oz/t) Au over 8.05 metres including 53.57 g/t (1.56 oz/t) Au over 2.65 metres including 66.20 g/t (1.93 oz/t) Au over 1.45 metres and 38.30 g/t (1.12 oz/t) Au over 1.20 metres
Note: Reported core lengths represent 50-75% true widths.
Phase I Drilling

The initial 30,000 metre (18,452 metres completed), Phase I drilling program on Cow Mountain was exclusively intended to upgrade areas of geological uncertainty and secondly to augment the geological model in areas that were entirely devoid of historical drilling.

The Pinkerton, Sanders, Rainbow and No. 1 Zones have been drilled in the near surface by previous operators at a sufficient hole spacing as to demonstrate a high degree of geological confidence and as such were not the focus of this first drilling campaign. In total, 101 drillholes have been completed to date on approximately 50 metre centres throughout select areas of Cow Mountain.

New High Grade Gold Extension Discovered

A previously undeveloped and unexplored area of gold-bearing quartz veins hosted between the Sanders and Rainbow Zones at approximately 250 metres vertical depth below surface has been identified during the Phase I program:

BGM-15-325 9.70 g/t (0.28 oz/t) Au over 7.35 metres including 28.50 g/t (0.83 oz/t) Au over 0.50 metres and 9.60 g/t (0.28 oz/t) Au over 0.50 metres and 44.60 g/t (1.30 oz/t) Au over 1.00 metres
BGM-16-326 31.67 g/t (0.92 oz/t) Au over 2.90 metres including 11.40 g/t (0.33 oz/t) Au over 0.50 metres and 112.50 g/t (3.28 oz/t) Au over 0.70 metres
BGM-16-340 5.70 g/t (0.17 oz/t) Au over 10.00 metres including 12.70 g/t (0.37 oz/t) Au over 3.40 metres and 30.30 g/t (0.88 oz/t) Au over 0.50 metres and 18.50 g/t (0.54 oz/t) Au over 0.50 metres and 14.70 g/t (0.43 oz/t) Au over 0.50 metres
BGM-16-361 6.46 g/t (0.19 oz/t) Au over 12.70 metres including 20.94 g/t (0.61 oz/t) Au over 2.40 metres including 20.20 g/t (0.59 oz/t) Au over 0.70 metres and 47.50 g/t (1.39 oz/t) Au over 0.70 metres
Note: Reported core lengths represent 50-75% true widths.

Drilling in this new extension has now defined a corridor of auriferous quartz veins with a strike length of approximately 140 metres and was targeted because of a scarcity of historical drilling in this location. These new mineralised vein sets are untested at depth and also along strike to the northwest and have only been drilled on widely spaced 50 metre centres.

Current Status

With three drill rigs on Cow Mountain, the budgeted 30,000 metre Phase I campaign is continuing and preferentially concentrated on optimizing the continuity of gold mineralisation in the near surface.

Mr. Chris Lodder, President of the Company noted, “The results to date from the Phase I program that targeted areas that lacked any historical drillholes is very positive. Not only have we identified a new mineralized extension with high exploration potential that is untested at depth, but we have also added additional gold mineralization across the extents of Cow Mountain”.

Qualified Persons

Exploration activities at the Cariboo Gold Project are jointly administered on site by the Company’s Project Managers Maggie Layman, P.Geo. and Wanda Carter, P.Geo. As per National Instrument 43-101 Standards of Disclosure for Mineral Projects, Paul Geddes, P.Geo. Vice President Exploration, is the Qualified Person for the Company and has prepared, validated and approved the technical content of this news release. The Company strictly adheres to CIM Best Practices Guidelines in conducting, documenting, and reporting its exploration activities on the Cariboo Gold Project.
Quality Assurance – Quality Control

Once received from the drill and processed, all drill core samples are sawn in half, labelled and bagged. The remaining drill core is subsequently stored on site at the Company’s secure facility in Wells, BC. Numbered security tags are applied to lab shipments for chain of custody requirements. The Company inserts quality control (QC) samples at regular intervals in the sample stream, including blanks and reference materials with all sample shipments to monitor laboratory performance. The QAQC program was designed and approved by Lynda Bloom, P.Geo. of Analytical Solutions Ltd., and is overseen by  Paul Geddes, P.Geo, Vice President Exploration of the Company.

Drill core samples are submitted to ALS Geochemistry’s analytical facility in North Vancouver, British Columbia for preparation and analysis. The ALS facility is accredited to the ISO/IEC 17025 standard for gold assays and all analytical methods include quality control materials at set frequencies with established data acceptance criteria. The entire sample is crushed and 250 grams is pulverized. Analysis for gold is by 50g fire assay fusion with atomic absorption (AAS) finish with a lower limit of 5ppb and upper limit of 10,000ppb. Samples with gold assays greater than 10,000ppb are re-analyzed using 50g fire assay with gravimetric finish, as well as 1,000g screen metallic fire assay. Samples are also analyzed using a 48 multi-elemental geochemical package by a 4-acid digestion, followed by Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) and Inductively Coupled Plasma Mass Spectroscopy (ICP-MS).

Contact:

Tom Obradovich
Chief Executive Officer
+1 416 361 2511
tobradovich@barkervillegold.com

About Barkerville Gold Mines Ltd.

The company is focused on developing its extensive land package located in the historical Cariboo Mining District of central British Columbia. BGM’s mineral tenures cover 1,164 square kilometres along a strike length of 60 kilometres which includes several past producing hard rock mines of the historic Barkerville Gold Mining Camp near the town of Wells, British Columbia. The QR Project, located approximately 110 kilometres by highway and all weather road from Wells was acquired by BGM in 2010 and boasts a fully permitted 900 tonne/day gold milling and tailings facility. Test mining of the Bonanza Ledge open pit was completed in March of 2015 with 91,489 tonnes of ore milled producing 25,464 ounces of gold. BGM has completed a number of drilling and exploration programs over the past 20 years and is currently compiling this data with all historical information in order develop geologic models which will assist new management and provide the framework to continue to explore the Cariboo Gold Project. An extensive drill program is currently underway with the goal of delineating additional high grade gold mineralization.

Cautionary Statement on Forward -Looking Information

Neither the TSX Venture Exchange (“TSXV”) nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This news release contains forward-looking information which is not comprised of historical facts. Forward-looking information involves risks, uncertainties and other factors that could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information. Forward looking information in this news release includes, but is not limited to, the Company’s objectives, goals or future plans, statements regarding exploration results and exploration plans. Factors that could cause actual results to differ materially from such forward-looking information include, but are not limited to, capital and operating costs varying significantly from estimates, the preliminary nature of metallurgical test results, delays in obtaining or failures to obtain required governmental, environmental or other project approvals, uncertainties relating to the availability and costs of financing needed in the future, changes in equity markets, inflation, fluctuations in commodity prices, delays in the development of projects and the other risks involved in the mineral exploration and development industry, and those risks set out in the Company’s public documents filed on SEDAR. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

Nymox  Pharmaceutical Corp’s {NASDAQ: NYMX} director George Robinson has again added to his substantial holding by adding a further 5,000 shares purchased in the market.

Robinson now owns 2,812,550 shares in total worth about $8,887,658.

Nymox Director Robinson increases his holding.

According to Nymox Pharmaceutical Corporation’s {NASDAQ: NYMX} most recent Form 4 filing with the SEC dated Jun 24 06:13 PM, company Director, Robinson James George disclosed buying 5,000 shares at a cost of $2.94.

At the time of this transaction (Jun 22), this trade was worth $14,675 in total. As of Jun 22, Robinson James George now owns 2,812,550 shares in total worth about $8,887,658.0.

VANCOUVER, B.C. – Scorpio Gold Corp. {TSX.V: SGN} reported final results from 2016 exploration drilling on the NW Brodie trend at its 70% owned Mineral Ridge project, located in Nevada.

VANCOUVER, BRITISH COLUMBIA– – Scorpio Gold Corp. {TSX.V: SGN) reports final results from 2016 exploration drilling on the NW Brodie trend at its 70% owned Mineral Ridge project, located in Nevada.

The NW Brodie trend extends over a 500 meter strike length between the Brodie and Bluelite deposits. Exploration drilling in 2014-2015 on the NW Brodie trend was based on a geological model of shallow dipping, multiple stacked veins, which is consistent with mineralisation in the Bluelite and Brodie deposits.

Inconsistencies in the drilling results prompted a detailed examination of the data and an oriented core drilling program. An updated geological model was completed in 2016. The mineralisation within the NW Brodie trend is now interpreted as a corridor of multiple tensional quartz veins with an average strike and dip of 255°/-60°. Due to the more steeply dipping nature of the mineralization, prior drilling with vertically oriented RC holes intersected the mineralisation at acute angles, resulting in thicker intersections than true widths.

Based on depths to mineralisation and current gold prices, the NW Brodie area is not considered economic at this time and no further work is currently planned in the area.

 
About Scorpio Gold

Scorpio Gold holds a 70% interest in the producing Mineral Ridge gold mining operation located in Esmeralda County, Nevada with joint venture partner Elevon, LLC (30%). Mineral Ridge is a conventional open pit mining and heap leach operation.

The Mineral Ridge property is host to multiple gold-bearing structures, veins and lenses at exploration, development and production stages. Scorpio Gold also holds a 100% interest in the advanced exploration-stage Goldwedge property in Manhattan, Nevada, with a fully permitted underground mine and 400 ton per day mill facility. The Goldwedge mill facility has been placed on a care and maintenance basis and can be restarted immediately when needed.

Scorpio Gold’s President & CEO, Peter J. Hawley, PGeo,, is a Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the content of this release.

ON BEHALF OF THE BOARD

SCORPIO GOLD CORPORATION

Peter J. Hawley, President & CEO

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:

Scorpio Gold Corporation
Peter J. Hawley
President & CEO
+1 819 825 7618
phawley@scorpiogold.com
www.scorpiogold.com

The price of Gold reacted positively to the ‘Brexit’ decision taken by the United Kingdom referendum voters.

With increased market volatility expected, investors are looking to the safe haven of gold, and the yellow metal my well rie in prce in the near term.

To monitor the live gold price, please click HERE

Nymox Pharmaceutical Corporation  {NASDAQ: NYMX} Director James George Robinson bought 22,500 shares of Nymox Pharmaceutical Corp stock in a transaction on Friday, June 24th.

This purchase adds to his recent purchases of stock in the market, bringing his total holding to over 2 million shares.

Nymox Pharmaceutical Corp {NASDAQ: NYMX} Director James George Robinson bought 22,500 shares of Nymox Pharmaceutical Corp stock in a transaction on Friday, June 24th.

The shares were purchased at an average cost of $2.97 per share, for a total transaction of $66,825.00.

Following the acquisition, the director now owns 2,810,050 shares in the company, valued at $8,345,848.50.

Condor Gold {AIM: CNR} confirmed that all resolutions at their AGM had been passed.

23 June 2016 Condor Gold plc (‘’Condor’’ or “the Company”)

Results of Annual General Meeting (“AGM”)

Condor (AIM:CNR) is pleased to announce that at the Company’s AGM held earlier today, all resolutions were passed. – Ends –

For further information please visit www.condorgold.com

or contact:

Condor Gold plc

Mark Child, Executive Chairman and CEO

020 7493 2784

VAL-D’OR, QUÉBEC– Cartier Resources Inc. (TSX.V: ECR}  announced that the progressive rise in the mining industry markets has generated opportunities to complete joint venture agreements that will develop the potential of its key projects.

June 23, 2016 07:48 ET

Cartier Gains from Market Rise

VAL-D’OR, QUÉBEC– Cartier Resources Inc. (TSX.V: ECR} is pleased to announce that the progressive rise in the mining industry markets has generated opportunities to complete joint venture agreements that will develop the potential of its key projects.

The five key projects, on which certain have historical resource estimates, are all drill-ready with targets bearing the same signature as that of the deposits that have been outlined on each project.

The company has over $1.5 M in cash of which half will be invested in exploration field work over the next months.

“Many companies have expressed an interest in these key projects and several negotiations are in progress” commented Philippe Cloutier, President and CEO, adding “We are confident that we will conclude win-win deals in the next months“.

Quality Assurance / Quality Control

The scientific and/or technical information presented in this press release has been reviewed and approved by Mr. Gaétan Lavallière, P. Geo., Ph. D., and Vice President for Cartier.

Mr. Lavallière is a qualified person as defined by National Instrument 43-101.

Neither the TSX Venture Exchange nor its regulatory services provider accepts responsibility for the adequacy or accuracy of this press release.

CONTACT:
Philippe Cloutier, P.Geo.,
President and CEO
+1 819 856 0512
philippe.cloutier@ressourcescartier.com
www.ressourcescartier.com

Nymox Pharmaceutical Corporation {NASDAQ: NYMX} announced results from the Company’s 7 year prospective placebo controlled double blind studies of treatment of 995 U.S. men with the Company’s lead drug fexapotide.

Nymox Pharmaceutical Corporation {NASDAQ: NYMX} announced results from the Company’s 7 year prospective placebo controlled double blind studies of treatment of 995 U.S. men with the Company’s lead drug fexapotide. Men who received fexapotide showed a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease.

The men in the study received fexapotide or placebo for the treatment of their prostate enlargement (BPH) symptoms. All men were thoroughly evaluated to exclude any prostate cancer prior to qualifying for enrollment in the studies. The participants were enrolled at over 70 top well-known U.S. urological investigational centers, and were followed for up to 7 years (median of 5 years) after treatment. The study analyzed all cases of prostate cancer that were subsequently diagnosed. The expected rate of new prostate cancer in the U.S. general male population in this age group is in the 5-20% range after 7 years. In the BPH population in published large trials of drugs for the prevention of prostate cancer, the incidence of new prostate cancer cases after 4-7 years has been reported in major studies to be 20-25%. The new data analysis from the Nymox fexapotide study has now shown the statistically significant and very low incidence of 1.3% for prostate cancer in this comparable fexapotide treated BPH population.

“These results are astonishingly good. Other drug treatments and controls tested in similar studies have been associated with a prostate cancer incidence 10 times higher than the results reported today by Nymox for fexapotide. This is truly good news. The data strongly indicate that in addition to benefit for BPH symptoms, fexapotide will also help to prevent cancer in these patients,” said Dr. Ronald Tutrone, one of the Principal Investigators in the Nymox Fexapotide Prostate Cancer and BPH studies. Dr. Tutrone is Chief of the Division of Urology, Greater Baltimore Medical Center; Medical Director of Chesapeake Urology Research Associates and Chairman of the William E. Kalhert Endowment for Urological Research.

Fexapotide is a safe and painless single injection treatment given in the urologist’s office. The drug is in Phase 3 for BPH and Phase 2 for prostate cancer. It has been tested in over 1700 drug and placebo treatment administrations in the U.S. As a treatment for BPH, fexapotide shows long-term efficacy without the safety risk and side effect concerns or added cancer risk associated with currently approved BPH treatments. As a treatment for prostate cancer fexapotide was found to lead to highly statistically significant reduction in disease progression in a large 147 patient multi-year Phase 2 study of U.S. men with low grade cancer.

Dr. Paul Averback, CEO of Nymox said, “The new results now add a third dimension to fexapotide utility: clinical prostate cancer prevention. The drug has now demonstrated statistically significant prospective long-term outcome data showing dramatic reduction in the incidence of newly diagnosed prostate cancer after minimal BPH treatment with fexapotide. Nymox announced in Q3 last year that it will seek regulatory approvals for fexapotide for BPH based on the long-term BPH safety and efficacy data announced Q3 last year. We believe that the exciting new prostate cancer prevention results reported today will add to the evidence in fexapotide’s favor towards our goal of widespread major benefit for middle-aged and elderly men.”

Dr. Averback added, “We are extremely grateful to the thousands of people who have been part of these clinical trials. The Company also thankfully acknowledges our shareholders for their long-term commitment that supports these studies.”

For more information please contact:

info@nymox.com

or

+1 800-936-9669

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox’s regulatory filings, Nymox’s substantial dependence on fexapotide, Nymox’s commercialization plans and efforts and other matters that could affect the availability or commercial potential of fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox’s current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2015, and its Quarterly Reports.

Contact:

Paul Averback

Nymox Pharmaceutical Corporation

www.nymox.com

 
Nymox Pharmaceutical Corporation.

Minera IRL Ltd.{BVLAC: MIRL], a Peruvian based gold mining and develment company, is pleased to announce the appointment of Mr. Derrick Weyrauch as a Non-Executive Director of the Company.

Jun 21, 2016 – 09:30 ET

PLYMOUTH MEETING, PA  – June 20, 2016 – Inovio Pharmaceuticals, Inc. {NASDAQ: INO} and GeneOne Life Science, Inc. (KSE: 011000) today announced that they have received approval to initiate a phase I human trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700) to prevent infection from this concerning virus.

Inovio Pharmas and GeneOne Life Science Receive Approval for First-in-Man Zika Vaccine Clinical Trial

PLYMOUTH MEETING, PA  – June 20, 2016 – Inovio Pharmaceuticals, Inc. {NASDAQ: INO} and GeneOne Life Science, Inc. {KSE: 011000} today announced that they have received approval to initiate a phase I human trial to evaluate Inovio’s Zika DNA vaccine (GLS-5700) to prevent infection from this concerning virus.

In pre-clinical testing this synthetic vaccine induced robust antibody and T cell responses in small and large animal models, demonstrating the product’s potential to prevent infection from this harmful pathogen in humans.

This phase I, open-label, dose-ranging study with 40 healthy subjects will evaluate the safety, tolerability and immunogenicity of GLS-5700 administered intradermally with CELLECTRA®, Inovio’s proprietary DNA delivery device.

Dr. J. Joseph Kim, Inovio’s President & CEO, said, “We are proud to have attained the approval to initiate the first Zika vaccine study in human volunteers. As of May 2016, 58 countries and territories reported continuing mosquito-borne transmission of the Zika virus; the incidences of viral infection and medical conditions caused by the virus are expanding, not contracting. We plan to dose our first subjects in the next weeks and expect to report phase I interim results later this year.”

Mr. Young K. Park, GeneOne Life Science’s President & CEO, said “It is an honor for our company to help usher this Zika vaccine through the clinical and regulatory process. We look forward to conducting this trial with the goal of achieving products to combat this dreaded virus.”

Inovio and GeneOne are developing the Zika vaccine, GLS-5700, with academic collaborators from the US and Canada with whom they have previously collaborated to advance Inovio’s Ebola and MERS vaccines into clinical development.

About the Zika Virus

First identified in Uganda, Zika virus subsequently spread to equatorial Asia and over the past two years has rapidly spread through the South Pacific, including Hawaii, and to South America, Central America, and the Caribbean. Zika virus is a flavivirus, a family of viruses including yellow fever, dengue, and West Nile virus, which are introduced to people through mosquito bites. Because the Aedes species of mosquitoes that spreads Zika virus is found throughout the world there is concern that Zika will continue to spread to new countries and regions. Zika can also be sexually transmitted.

The most common symptoms of Zika virus are fever, rash, joint pain, and conjunctivitis. More seriously, Zika has been linked to a severe birth defect called microcephaly which arises from infection during pregnancy. Microcephaly is a rare condition marked by an abnormally small head and incomplete brain development. Zika is also associated with Guillain-Barré syndrome, which causes muscle weakness of the limbs and in severe cases may cause almost total paralysis including the inability to breath. Recent reports suggest Zika may also be linked to other neurological abnormalities.

No vaccine or therapy currently exists for the Zika virus.

About GeneOne Life Science

GeneOne Life Science, Inc. is an international DNA vaccine developer and leading contract manufacturer of DNA plasmid-based agents for preclinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne’s wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world. VGXI manufactured the Zika vaccine and other emerging disease vaccines including Ebola and MERS.

About Inovio Pharmaceuticals, Inc.

Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that has reported generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, The Wistar Institute, University of Pennsylvania, DARPA, GeneOne Life Science, Plumbline Life Sciences, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit www.inovio.com

CONTACT:
Investor and Media Relations:
Bernie Hertel,

Inovio Pharmaceuticals,

+1 267 440 4298,

investor.relations@inovio.com

* * *

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100 and INO-3112, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immunotherapy and vaccine products, our ability to advance our portfolio of immuno-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2015, our Form 10-Q for the quarter ended March 31, 2016, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

El Nino Ventures {TSX.V: ELN} confirmed they had closed a private placement raising $453,955 by issuing circa 23 million new shares.

CEO HArry BArr participted in the financing.

EL NINO CLOSES PRIVATE PLACEMENT AND ISSUES EARLY WARNING REPORT

El Nino Ventures Inc. has closed its non-brokered private placement raising gross proceeds of $453,955.

The company issued 22,697,750 units at a price of two cents per unit, pursuant to a discretionary waiver obtained from the TSX Venture Exchange on April 21, 2016, from the five-cent-per-share minimum pricing requirements. Each unit consists of one common share and one non-transferable share purchase warrant. Each warrant entitles the holder to purchase one additional common share of the company at a price of five cents per share for a period of 24 months from closing.

Harry Barr, chairman, chief executive officer and a director of the company, purchased 10.5 million units from the company at a price of two cents per unit, pursuant to the private placement.

Prior to the closing of the private placement, Mr. Barr held directly and indirectly 6,366,854 shares and 550,000 options to purchase an additional 550,000 common shares of the company, representing approximately 18.36 per cent of the company’s issued and outstanding shares on a post conversion beneficial ownership basis.

As a result of Mr. Barr’s acquisition pursuant to the private placement, Mr. Barr now holds 16,866,854 common shares, and 11.05 million warrants and options of the company, representing approximately 39.37 per cent of the company’s current issued and outstanding shares of the company on a post conversion beneficial ownership basis.

Finders’ fees totalling 35,000 shares, 77,000 broker warrants and $840 cash were paid in connection with the private placement.

The shares and warrants issued with respect to the private placement are subject to a four-month-and-one-day hold period expiring on Oct. 21, 2016, in accordance with securities laws. The shares issued are also subject to voluntary pooling restrictions. Completion of the private placement and any finders’ fees payable are subject to regulatory approvals.

Proceeds from the private placement in the amount of up to $279,000 will be used for further exploration and development on the company’s Murry Brook polymetallic project in New Brunswick. Up to $66,000 will be used to settle related-party debt and up to $108,955 will be used for general working capital.

Further to the company’s news release dated April 21, 2016, the company plans to complete phase 2 of its debt restructure. More specifically, the company has agreed to settle its debt obligations to existing creditors (50 cents on the $1) in the amount of up to $80,054 by issuing up to 1,601,080 common shares at five cents per share. After completion of the shares-for-debt transaction, the company will have settled all outstanding debts.

Kootenay Silver Inc. {TSX.V: KTN} )announced that it is preparing to conduct a 3,000 metre drill program on its 100% owned La Cigarra silver project located in Chihuahua State, Mexico.

Kootenay Plans 3,000 Metre Drill Program at La Cigarra Project, Mexico

Jun 16, 2016

Kootenay Silver Inc. {TSX.V: KTN} ) is pleased to announce that it is preparing to conduct a 3,000 metre drill program on its 100% owned La Cigarra silver project located in Chihuahua State, Mexico.

The targeted drill program, scheduled to commence in Q3 2016 is designed to test the high priority RAM target and to expand La Cigarra’s current mineral resource estimate by targeting continuity of high-grade trends recently identified within the resource.

Kootenay President and CEO James McDonald Stated  “We are very excited to proceed with a targeted drill program on La Cigarra mineral resource and the nearby RAM target. The objective will be to further enhance the size and grades of our established silver resource estimate on La Cigarra prior to proceeding with a Preliminary Economic Assessment on the project. Concurrently, we will conduct the first drill test on our high priority RAM target that is a large, structurally controlled trend that demonstrates significant potential to further add to our current silver resources.”

Drill testing on La Cigarra will test the continuity of several high-grade trends identified within the deposit with focus on stepping out from existing mineralization along the extensions of what appear to be underlying high-grade zones. This includes the southern boundary of the Las Carolinas Zone where hole 155 returned 23 metres of 138 g/t silver. (See Kootenay/Northair News Release dated Dec 15, 2014). This area remains open down dip and along strike to the southeast, which could potentially extend an additional two (2) kilometers.

In conjunction with the preparation of the drill program, Kootenay’s technical team has been focused on advancing the La Cigarra deposit with the objective of moving towards a Preliminary Economic Assessment (“PEA”). The Company has been assessing the potential to increase grade, in order to demonstrate the economic potential of the project by seeing if there are contiguous zones of higher grade within the current NI 43-101 silver resource estimate. This approach shows promise as several north trending higher grade zones have been identified. These zones also correspond nicely with the resource blocks above a 75 g/t Ag cutoff contained within the current resource estimate. Although the existing resource estimate did not publish silver resources at a 75 g/t Ag cutoff, the ounces at a 50 g/t Ag cutoff total 44.47 million ounces of Measured and Indicated ounces grading 103 g/t Ag with another 9.6 million ounces of Inferred grading 97 g/t. *(See resource estimate below and as filed on SEDAR).

The RAM Zone, located approximately 750 meters to the west of the main La Cigarra Resource, underlies an area of anomalous silver mineralization greater than the area of the La Cigarra deposit. The target area hosts several old mine workings developed along a structurally focused quartz veining and stockwork in west dipping mineralisation with similarities to the east dipping main La Cigarra trend.

Previously reported sampling along a 35 meter length of a small underground exploration adit averaged 285 g/t silver across a 1.5 meter width. Surface trenching of this area completed above the adit returned 35.45 metres averaging 67.3 g/t silver (including 16.20 meters of 99.6 g/t silver and 4.85 meters of 141.4 g/t silver). Mineralization at RAM occurs at surface within the north trending RAM fault that has been traced for approximately two (2) kilometers in length within a larger target zone that measures 3.8 kilometers in length.

A larger drill program will be designed once re-logging to assess the potential to model the high-grade zones and the 3,000 meter program are complete. This subsequent program is anticipated to begin at the end of Q3 and could possibly run seamlessly from one program to the next.

La Cigarra Resource Estimate

La Cigarra’s updated NI 43-101 resource estimate was completed by Allan Armitage, PhD, P. Geo. and Joe Campbell, B.Sc., P. Geo., of GeoVector Management Inc. Resource Statement for the La Cigarra silver project located in Chihuahua State, Mexico: Effective Date January 14, 2015.

The resource estimate was calculated based on results from 156 of 173 holes totaling 27,617 meters drilled along the open ended La Cigarra mineralized system which has a defined strike length of at least three (3) kilometers. The 156 holes included in the Property’s resource estimate were positioned within a potentially surface minable area comprised of the San Gregorio and Las Carolinas mineralized zones, which combined form a total strike length of 2.4 kilometers. The resource estimate was constrained by a constrained pit shell utilizing a $22 /oz silver price and reported at a 35 g/t silver cut-off grade, and considers metallurgical recoveries of 84% silver.
A summary of the mineral resource estimate is listed on the company website, to read them please CLICK HERE

Lithium expert Joe Lowry has revised his thoughts about the number of lithium juniors that wil make it into production.

The revision is upwards, and good news for investors in the sector.

Lithium Expert Joe Lowry has written a very positive update from his previous views on the lithium sector, in a very candid article.

To read the full article please CLICK HERE